Comments on: CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist

Comments on: CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist https://9krapalm.com/curegene-completes-first-participant-dose-in-phase-i-trial-of-cg-0416-advancing-clinical-development-of-novel-oral-liver-targeting-thr-%ce%b2-agonist/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Fri, 21 Aug 2026 12:50:44 +0000 hourly 1 https://wordpress.org/?v=7.0.4